Practicalities of Conducting Biological Assessments for Drug Use Kenzie L. Preston, Ph.D. Chief, Clinical Pharmacology and Therapeutics Research Branch.

Slides:



Advertisements
Similar presentations
Drug Testing in Biological Matrices: Hair and Urine Charles McKay MD FACMT, FACEP, ABIM, MROCC Medical Toxicologist, Medical Review Officer, and Emergency.
Advertisements

Presenters: Promoting Regulatory Excellence Use of Substance Abuse Testing in Licensure Actions Donna R. Smith, PhD FirstLab, Inc.
Laboratory Methods for Detecting Prenatal Exposure to Cocaine Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology.
© 2007 Thomson - Wadsworth Chapter 13 Nutrition Care and Assessment.
CRICOS No J Deterring Drug Drivers: A Study into the Initial Impact of Oral Random Roadside Drug Testing in Queensland Professor Jeremy Davey ICADTS.
Great Ormond Street Hospital for Children NHS Trust The School of Pharmacy UCL INSTITUTE OF CHILD HEALTH Centre for Paediatric Pharmacy Research Drug Development.
THCA in Head Hair: A Comparison with Fingernail. Conflict of Interest  Employees of USDTL Privately held company Commercial laboratory Sells hair testing.
All You Would Ever Want to Know about Urine Toxicology Screening Mohammad Al-Ghoul, PhD Chief Technical Officer Diane A. Tennies, PhD Lead TEAP Health.
Prescription Drug Abuse And The Toxicology Of Medication Monitoring
E THYLGLUCURONIDE (E T G) ASSESSED BY TWO METHODS FOLLOWING FRAGRANCE AND HAND SANITIZER EXPOSURE IN MEN AND WOMEN Mollie Starkie, Pharm.D. Candidate Mercer.
HPLC Coupled with Quadrupole Mass Spectrometry and Forensic Analysis of Cocaine.
Clinical Trials Medical Interventions
Karran A. Phillips, MD, MSc NIDA Intramural Research Program AMERSA Annual Meeting November 8, 2014.
Dennis M. Donovan, Ph.D., Michael P. Bogenschutz, M.D., Harold Perl, Ph.D., Alyssa Forcehimes, Ph.D., Bryon Adinoff, M.D., Raul Mandler, M.D., Neal Oden,
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2008.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2008.
Challenges and Successes Treating Adolescent Substance Use Disorders Janet L. Brody, Ph.D. Center for Family and Adolescent Research (CFAR), Oregon Research.
Forensic Toxicology. Toxicology A science that deals with poisons and their effect and with the problems involved Forensic Toxicology The use of toxicology.
Forensic Drug Analysis ON-SITE DRUG TESTS SCREENING TESTS
Chemometrics Method comparison
Diagnostic Assays to Plan Specific Drug Treatment Elizabeth Hammond MD.
1 Drug-Free Partnership ScreenSafe, Inc
The Science Behind Drugs Testing -Past, Present and Future- Dr Francois Oosthuizen – Senior Chemist & Research Officer, Toxicology laboratory, ChemCentre.
Kathleen Carroll & Brian Kiluk Division of Substance Abuse Yale University School of Medicine Supported by NIDA Supplement to R01 DA15969 and P50 DA09241,
Evidence-Based Practice: Psychosocial Interventions Maxine Stitzer, Ph.D. Johns Hopkins Univ SOM NIDA Blending Conference June 3, 2008 Cincinnati, Ohio.
Analytical Goals. Valid data are essential in making medical decisions, the most important concepts used in judging analytical performance :- 1)Analytical.
Medication Assisted Therapy for Opioid Addiction: Methadone and Buprenorphine Andrew J. Saxon, M.D. Veterans Affairs Puget Sound Health Care System and.
Update on DOT Drug & Alcohol Testing Programs FL DOE Meeting February 2010 Dr. Donna Smith FirstLab, Inc.
Effect of Depression on Smoking Cessation Outcomes Sonne SC 1, Nunes EV 2, Jiang H 2, Gan W 2, Tyson C 1, Reid MS 3 1 Medical University of South Carolina,
CHEE DRUG PRODUCT DEVELOPMENT u Drug ä agent intended for use in the diagnosis, mitigation, treatment, cure, or prevention of disease in man or animals.
DUID DETECTION THE PRELIMINARY ROADSIDE DRUG TEST SYSTEM WITH ORAL FLUID (SALIVA)
Theoretical Error Rates of Qualitative UDS Tests for Stimulants Neal Oden, PhD, Paul VanVeldhuisen, PhD, NIDA Data and Statistics Center 2, The EMMES Corporation.
For Pain or Not for Pain: Methadone Madness
Current Trends In Identifying And Treating Newborns With Withdrawal Syndromes 6/24/2010.
Study Design for a Randomized Controlled Trial of Osmotic-Release Methylphenidate (OROS-MPH) Osmotic-Release Methylphenidate (OROS-MPH) for Attention Deficit.
-Point- The Quest for Clean Competition in Sports: Are We the Dopes? G.S. Baird October © Copyright 2014.
Abstinence Incentives for Methadone Maintained Stimulant Users: Outcomes for Those Testing Stimulant Positive vs Negative at Study Intake Maxine L. Stitzer.
CONTROLLED SUBSTANCES AND ALCOHOL USE TESTING REGULATIONS FOR DRIVERS.
· Lecture 31 & 32 : Scope of clinical biochemistry ط Uses of clinical biochemistry tests ط Diagnosis, Prognosis, Screening, Monitoring ط Reporting results.
SCHOOL OF NURSING UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Not Ready for Prime Time? A Web-Based SBIRT Intervention in an Urban Safety-Net HIV Clinic Carol.
1 The impact of ongoing illicit drug use on virologic suppression in HIV-infected injection drug users receiving HAART Authors: Harout Tossonian, Jesse.
Impact of Prolonged Cannabinoid Excretion in Chronic Daily Cannabis Smokers' Blood on Per Se Drugged Driving Laws M.M. Bergamaschi, E.L. Karschner, R.S.
1 Electrical Industry Drug-Free “Alliance” ScreenSafe Inc. Program Administrators SCREEN-9 Employee Resource Systems, Inc. Members Assistance Program.
The New Drug Development Process (www. fda. gov/cder/handbook/develop
Table 1. Prediction model for maximum daily dose of buprenorphine-naloxone in a 12-week treatment condition Baseline Predictors Maximum Daily Dose Standardized.
CONTROLLED SUBSTANCES AND ALCOHOL USE TESTING REGULATIONS FOR DRIVERS.
Monitoring Abstinence Martin H. Plawecki MD, PhD Indiana University School of Medicine Department of Psychiatry Alcohol Medical Scholars Program.
How To Design a Clinical Trial
Combined Pharmacological and Behavioral Therapy and HIV Risk Reduction Jennifer Schroeder, David Epstein, Katherine Belendiuk, Jessica Willner-Reid, John.
European Patients’ Academy on Therapeutic Innovation The key principles of pharmacology.
1 SAMPLE ALTERNATIVES URINE BLOOD BREATH SALIVA HAIR SWEAT.
Clinical Pharmacokinetics of Alcohol in A CDAT Sample Robert Cohen Consultant Addiction Psychiatrist
How To Pass A Hair Drug Test. What is a Hair Drug Test? As its name connotes, this kind of drug testing uses hair follicles to establish and verify persistent.
Randomized Controlled CTN Trial of OROS-MPH + CBT in Adolescents with ADHD and Substance Use Disorders Paula Riggs, M.D., Theresa Winhusen, PhD., Jeff.
The most common form of drug test is the urine test, likely due to its inexpensiveness. Urine testing detects past drug use, not real-time. Urine tests.
TB in Yorkshire and the Humber Dr Simon Padfield 14 th Sept 2007.
Self reported (il)licit drug use in Belgian drivers Trudy Van der Linden a, Peter Silverans b, Cristina Isalberti a, Sara-Ann Legrand a, Alain Verstraete.
STATE BAR OF TEXAS ADVANCED FAMILY COURSE: 2015 AUGUST 3-6, 2015 SAN ANTONIO, TEXAS.
1 ELECTRICAL INDUSTRY DRUG- FREE WORKPLACE FITNESS FOR DUTY PROGRAM ScreenSafe, Inc.
Determination of drug of abuse in hair sample TEJASWINI JADHAV.
CLINICAL TRIALS.
Comparisons Of Different Modalities Michael Casarico LADC
How To Design a Clinical Trial
David Sottile, Anthony DeFulio, and Kenneth Silverman INTRODUCTION
C. Costa, R. Webb, V. Palitsin, M. Ismail, M. de Puit, S. Atkinson, M
Controlled substance compliance
DAY 2 Single-Case Design Drug Intervention Research Tom Kratochwill
Drugs of Abuse Service: Urine and oral fluid testing Dr Paul Cawood Toxicology, Clinical Biochemistry, RIE GP-Laboratory Medicine Update Meeting 11th.
DAY 2 Single-Case Design Drug Intervention Research Tom Kratochwill
Overview of Substance Use Outcomes in Other SUD trials
Presentation transcript:

Practicalities of Conducting Biological Assessments for Drug Use Kenzie L. Preston, Ph.D. Chief, Clinical Pharmacology and Therapeutics Research Branch National Institute on Drug Abuse ACTTION/MOST Meeting, March 2015

Why Use Biological Measures? Costly Inconvenient Unnecessary? Good evidence that people under report use Adds credibility to results

Ideal Drug Testing for Clinical Trials Specimen is: Easily and safely collected Low risk of contamination/adulteration Easily stored/transported (if necessary) Window of detection that matches specimen collection schedule Test is: Good efficiency (sensitivity and specificity) Low cost Quick and easy

Drug Testing Workplace: public safety & reduce accidents Roadside: drugged driving Judicial: drug use & crimes Anti-doping: fair competition & promote health Military: deter drug use & ensure fitness for duty Clinical: diagnosis or postmortem Drug treatment: monitor recovery/abstinence Monitor drug use in clinical trials: evaluate treatments for efficacy ScreenConfirmation ? ?

Drug Testing and Addiction Sweat Hair Oral FluidBreathDried Blood Spot Urine

Survey of Drug Testing in Biological Matrices Major analyte Detection time Detection of recent use/sensitivity to change in rate of use Collection convenient Contamination On site testing? Other Issues

Survey of Drug Testing in Biological Matrices Major analyteMetabolite Detection time2-4 days Urine Detection of recent Yes/No - carry over positives can be a problem use/sensitivity to with frequent testing change in rate of use ( Quantitative and frequent testing required) Collection convenient No - Toilet facilities and same-sex observers Contamination Unlikely On site testing? Yes Other Issues Well established concentration cut-offs Well established use as an outcome measure Many laboratories use the same or similar assays

Concentration Cutoff Affects Window of Detection Preston, Epstein, Cone Wtsadik, Huestis, Moolchan, JAT 2002 N = 18 cocaine users living on a closed unit No drug administration - monitored excretion of cocaine and metabolites Sample collection - All urine voids (N=953) were collected for up to 14 days Concentration Cutoff for Positive Specimen Hours BE 300 ng/ml cutoff Time to Concentration Cutoff Lower cutoff lengthen window Raise cutoff shorten window

ContingentControl Longest Duration of Sustained Abstinence Weeks Responders Nonresponders Clinical Trial - Contingent Reinforcement of Cocaine Abstinence

Sequential Urine Specimens Benzoylecgonine Concentration in Urine ng/mL Specimens were collected M, W, F for 17 weeks.

Sequential Urine Specimens Benzoylecgonine Concentration in Urine ng/mL Cutoff LOQ 11 occasions negative Specimens were collected M, W, F for 17 weeks. SAMHSA

Sequential Urine Specimens Benzoylecgonine Concentration in Urine ng/mL Cutoff LOQ 23 occasions of negative Specimens were collected M, W, F for 17 weeks. Cutoff SAMHSA

New Use Rules Purpose: To differentiate urine positives due to carryover from positives due to recent (or new) uses of cocaine

Sequential Urine Specimens Benzoylecgonine Concentration in Urine ng/mL Cutoff LOQ 28 occasions of new use 12 occasions of carry-over 11 occasions of negative Specimens were collected M, W, F for 17 weeks.

Comparison of Urine Screen and Self-Report Baseline Intervention

Survey of Drug Testing in Biological Matrices Major analyteParent>Metabolite Detection time1 week – months Hair Collection convenient Yes/No (depends of amount and style of hair ContaminationPossible On site testing?No, must be sent to outside lab Other IssuesAffected by hair color & treatments Only matrix with potential for replication Detection of recent No - limited by hair growth rate use/sensitivity to (7-10 days for hair to grow through scalp) change in rate of use Hair grows approximately 1 cm/mo.

Admission Week Scheidweiler, Cone, Moolchan, Huestis. JPET 313, , 2005 Cocaine and metabolite concentrations in hair N = 10 cocaine users Admission to closed unit 3 week drug washout Week administrations of 75 mg/70 kg SC cocaine on alternating days Week administrations of 150 mg/70 kg SC cocaine on alternating days Sample collection - electric razor Head hair shaved on admission Weekly collection of shavings Analysis Liquid chromatography tandem mass spectrometry Representative subject Benzoylecgonine Ecgonine methyl ester Norcocaine Cocaethylene

Cocaine - Concordance between hair testing and self-report – 86% Specificity >90%, Sensitivity 65 % Amphetamine - Concordance between hair testing and self-report – 86% Specificity >90%, Sensitivity 24%

Baseline and 3-month follow-up

Office-based vs. federally licensed narcotic treatment program Hair testing at Baseline and 3- and 6-month follow-ups in addition to self-report and urine toxicology No difference between groups Hair testing identified two additional participants in each group who had used illicit drugs. Positive hair test predicted drug use during the trial.

Survey of Drug Testing in Biological Matrices Major analyteParent>Metabolite Detection time3-10 days - usually one week Sweat Other IssuesAllergic reaction possible; patches may fall off Not well established use as outcome measure Currently available from only one company Collection convenient Yes/No (same-sex not needed, but patch may be visible) ContaminationPossible, especially if area not cleaned well On site testing?No, must be sent to outside lab Detection of recent Yes/No - carry over positives can happen use/sensitivity to detection of change limited by length change in rate of use of patch wear

BZE ,000 10, ,000 10, ,000 1,000, ,000 10, ,000 1,000, ,000 10,000 Sweat Cocaine Urine Subject C Subject D Sweat Urine Weeks Cocaine BZE ng/mL ELISA Sweat Patch vs. EMIT Urine Results Sensitivity % Specificity % Preston, Huestis Wong Umbricht, Goldberger, Cone. J Anal Toxicol Monitoring Cocaine Use in Sweat Patches ng/mL

63 participants in a buprenorphine trial Applied 536 patches 188 (54%) properly worn, unadulterated patches Agreement between urine and patch results cocaine – 92% opiates – 33%

Survey of Drug Testing in Biological Matrices Major analyteParent>Metabolite Detection time1-2 days (depends on cut off and analyte) Oral Fluid Detection of recent Yes use/sensitivity to change in rate of use Collection convenient Yes ContaminationYes/No On site testing?Yes Other IssuesNot established as an outcome measure Affected by flow rate & pH

Detection of Cocaine Use in Oral Fluid Cocaine BZE (Cocaine Metabolite) Huestis et al.

Potential Areas of Research  Optimize concentration cut-offs/detection windows  Combine different biological matrices to optimize windows of drug detection  Investigate methods to improve adherence to specimen collection  Investigate methods to improve remote collection of specimens

Questions?